Several CAR T-cell therapies have already been granted approval by the FDA and EMA, but the field is broadening. New therapies are tapping into stem cells, T-cell receptors (TCR), tumor-infiltrating lymphocytes, macrophages, and NK-cells to explore their therapeutic potential.
While these therapies can be more effective at targeting solid tumors, they face barriers throughout development.
Gain the insights needed to understand and overcome the unique clinical, translational, logistical, and manufacturing challenges associated with developing a novel cell therapy in this free ungated ehttps://www.precisionformedicine.com/resources/oncology-cell-therapy-trial-ebook/book.
Within this resource, we go into detail on the current and future state of cell therapy development.
Rob Maiale is a leading content strategist and creator with more than 15 years of experience in healthcare marketing and brand development. His specialties include pharma, diagnostics, med-tech, patient education, translational research and clinical development.
Precision for Medicine is part of the Precision Medicine Group, an integrated team of experts that extends Precision for Medicine’s therapeutic development capabilities beyond approval and into launch strategies, marketing communication, and payer insights. As one company, the Precision Medicine Group helps pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.
